Abstract：We identified the Beijing family strains of multiple drug-resistant tuberculosis and find out the distribution of second-line injectable drugs resistance-associated nucleotide alteration among the MDR strains in Ningbo. The 106 MDR isolates were selected from the first drug resistant survey in Ningbo during 2014 and 2016. The conventional drug susceptibility testing was used to detect the drug-resistant profiles against 3 second-line injectable drugs (kanamycin, amikacin, capreomycin). The RD105 deletion-targeted multiplex PCR method was used to distinguish the genotype among 106 MDR strains. The gene mutations of second-line injectable drugs resistance-associated among MDR-TB strains were detected by direct DNA sequencing. Results showed that out of the 106 MDR isolates, 83(78.3%, 83/106) belonged to Beijing genotype, while the other 23(21.7%, 23/106) were non-Beijing genotype. There were 10 strains with second-line injectable drugs resistance in 83 Beijing genotype MDR strains and there were no strains with second-line injectable drugs resistance in 23 non-Beijing genotype MDR strains. The Beijing MDR strains had significantly higher proportions of second-line injectable drugs resistance than non-Beijing strains. There were 4 with mutations in 10 MDR-TB with second-line injectable drugs resistance and there were 24 with mutations in 96 MDR-TB without second-line injectable drugs resistance (χ2=1.048, P>0.05). Beijing genotype MDR strains revealed a significant association with second-line injectable drugs resistance. The mechanism of second-line injectable drugs resistance in MDR-TB is mainly in no connection with the mutation of the genes.
[1] World Health Organization. Global tuberculosis report 2016[R]. Geneva: World Health Organization, 2016. [2] Georghiou S, Magana M, Garfein R, et al. Evaluation of genetic mutation associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review[J]. PLoS One, 2012, 7(3): e33275. doi:10.1371/journal.pone.0033275 [3] Chen Q, Pang Y, Liang Q, et al. Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated in Fujian, China[J]. Tuberculosis(Edinb), 2014, 94(2): 159-161. doi:10.1016/j.tube.2013.03.004 [4] Zhao M, Li X, Xu P, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China[J]. PLoS One, 2009, 4(2): e4370. doi:10.1371/journal.pone.0004370 [5] Yuan X, Zhang T, Kawakami K, et al. Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China[J]. BMC Infect Dis, 2013, 13(2): 315-318. doi:10.1186/1471-2334-13-315 [6] Chen J, Tsolaki AG, Shen X, et al. Deletion-targeted multiplex PCR( DTM-PCR) for identification of Beijing/W genotypes of Mycobacterium tuberculosis [J]. Tuberculosis, 2007, 87(5): 446-449. doi:10.1016/j.tube.2007.05.014 [7] China Anti-tuberculosis Association Foundation Committe. Laboratory testing procedures for tuberculosis diagnosis[M]. Beijing: China education culture publishing House, 2006. (in Chinese) 中国防痨协会基础委员会.结核病诊断实验室检验规程[M].北京:中国教育文化出版社,2006. [8] Pang Y, Zhou Y, Zhao B, et al. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China[J]. PLoS One, 2012, 7(3): e32976. doi:10.1371/journal.pone.0032976 [9] Parwati I, van Crevel R, van Soolingen D, et al. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains(Review) [J]. Lancet Infect Dis, 2010, 10(2): 103-111. doi:10.1016/S1473-3099(09)70330-5 [10] Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular characterization of fluoroquinolone Mycobacterium tuberculosis isolates in China[J]. Antimicrob Agents Chemother, 2014, 58(1): 364-369.doi:10.1128/AAC.01228-13 [11] Yang C, Luo T, Sun G, et al. Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China[J]. Clin Infect Dis, 2012, 55(9): 1179-1187. doi:10.1093/cid/cis670 [12] Li DQ, Xia XS, Song YZ, et al. Genetic genotyping techniques for Mycobacterium tuberculosis and the application[J].Chin J Zoonoses,2016, 32(1): 76-82.doi:10.3969/j.issn.1002-694.2016.01.016 (in Chinese) 李道群,夏雪山,宋玉竹,等.结核分枝杆菌分子分型技术的研究和应用[J]. 中国人兽共患病学报,2016,32(1):76-82. [13] Wang ZF, Li B, Jiang MX, et al. Investigation on spoligotyping and phenotypes of drug resistance for four first-line drugs in 251 Mycobacterium tuberculosis isolates from Qinghai, China[J]. Chin J Zoonoses, 2017, 33(4): 332-336. doi:10.3969/j.issn.1002-2694.2017.04.008 (in Chinese) 王兆芬,李斌,蒋明霞,等.青海省251株结核分枝杆菌Spoligotyping基因型与4种一线药物耐药表型的研究[J].中国人兽共患病学报,2017,33(4):332-336. [14] Sirgel FA, Tait M, Warren RM, et al. Mutations in the rrs A1401G Gene and Phenotypic Resistance to Amikacin and Capreomycin in Mycobacterium tuberculosis [J]. Microb Drug Resist, 2012, 18: 193-197.doi:10.1089/mdr.2011.0063 [15] Zhang T, Fu J, Wang GZ, et al. Probe melting curve analysis for rapid detection of injectable second-line drug-resistant mutations in Mycobacterium tuberculosis strains[J].Chin J Zoonoses, 2015, 31(5): 412-417. doi:10.3969/cjz.j.issn.1002-2694.2015.05.005 (in Chinese) 张婷,付军,王国志,等.探针熔解曲线法快速检测结核分枝杆菌注射类二线药耐药突变[J]. 中国人兽共患病学报,2015,31(5):412-417. [16] Hu Y, Yang C, Pang Y, et al. Characteristics of gyrA and rrs gene mutations in multidrug-resistant tuberculosis isolates in Chongqing, China[J].Chin J Zoonoses, 2016, 32(11): 1001-1005. doi:10.3969/j.issn.1002-2694.2016.011.011 (in Chinese) 胡彦,杨春,逄宇,等.重庆市耐多药结核分枝杆菌gyrA与rrs基因突变特征分析[J]. 中国人兽共患病学报,2016,32(11):1001-1005. [17] Hu Y, Hoffner S, Wu L, et al. Prevalence and genetic characterization of second-line drug resistant and extensively drug-resistant Mycobacterium tuberculosis in rural China[J]. Antimicrob Agents Chemother, 2013, 57(8): 3857-3863. doi:10.1128/AAC.00102-13 [18] Okamoto S, Tamaru A, Nakajima C, et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria[J]. Mol Microbiol, 2007, 63(4): 1096-1106. doi:10.1111/j.1365-2958.2006.05585.x [19] Spies FS, Ribeiro AW, Ramos DF, et al. Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene[J]. J Clin Microbiol, 2011, 49(7): 2625-2630.doi:10.1128/JCM.00168-11 [20] Wong SY, Lee JS, Kwak HK, et al. Mutations in gidB confer low-level streptomycin resistance in mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2011, 55(6): 2515-2522. doi:10.1128/AAC.01814-10 [21] Wong SY, Javid B, Addepalli B, et al. Functional role of methylation of G518 of the 16SrRNA 530 loop by gidB in Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother, 2013, 57(12): 6311-6318. doi:10.1128/AAC.00905-13 [22] Engstrom A, Perskvist N, Werngren J, et al. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis [J]. J Antimicrob Chemother,2011, 66: 1247-1254. doi:10.1093/jac/dkr109 [23] Jureen P, Angeby K, Sturegard E, et al. Wild-type MIC distribution for aminoglycoside and cyclic polypeptide antibiotics used for treament of Mycobacterium tuberculosis infections[J]. J Clin Microbiol, 2010, 48(5):1853-1858. doi:10.1128/JCM.00240-10
2018, Vol. 34 
